Evidence map›Paper›PMID 36430693›Full record

ArticleInternational journal of molecular sciences2022

Exploiting ELIOT for Scaffold-Repurposing Opportunities: TRIM33 a Possible Novel E3 Ligase to Expand the Toolbox for PROTAC Design.

Tommaso Palomba, Giusy Tassone, Carmine Vacca, Matteo Bartalucci, Aurora Valeri, Cecilia Pozzi, Simon Cross, Lydia Siragusa, Jenny Desantis

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Trends and Applications in Computationally Driven Drug Repurposing.International journal of molecular sciences · 2023
    Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Tommaso PalombaDepartment of Chemistry, Biology and Biotechnology, University of Perugia, Via Elce di Sotto, 8, 06132 Perugia, Italy.ORCID 0000-0002-1949-7681
Giusy TassoneDepartment of Biotechnology, Chemistry and Pharmacy, University of Siena, Via Aldo Moro, 2, 53100 Siena, Italy.ORCID 0000-0002-2575-5528
Carmine VaccaDepartment of Chemistry, Biology and Biotechnology, University of Perugia, Via Elce di Sotto, 8, 06132 Perugia, Italy.
Matteo BartalucciDepartment of Chemistry, Biology and Biotechnology, University of Perugia, Via Elce di Sotto, 8, 06132 Perugia, Italy.
Aurora ValeriMolecular Horizon srl, Via Montelino, 20, 06084 Bettona, Italy.ORCID 0000-0003-4027-7613
Cecilia PozziDepartment of Biotechnology, Chemistry and Pharmacy, University of Siena, Via Aldo Moro, 2, 53100 Siena, Italy.ORCID 0000-0003-2574-3911
Simon CrossKinetic Business Centre, Molecular Discovery Ltd., Theobald Street, Elstree, Borehamwood, Hertfordshire WD6 4PJ, UK.
Lydia SiragusaMolecular Horizon srl, Via Montelino, 20, 06084 Bettona, Italy.ORCID 0000-0003-4596-7242
Jenny DesantisDepartment of Chemistry, Biology and Biotechnology, University of Perugia, Via Elce di Sotto, 8, 06132 Perugia, Italy.ORCID 0000-0002-2334-934X
University of Perugia · ITUniversity of Siena · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The field of targeted protein degradation, through the control of the ubiquitin-proteasome system (UPS), is progressing considerably; to exploit this new therapeutic modality, the proteolysis targeting chimera (PROTAC) technology was born. The opportunity to use PROTACs engaging of new E3 ligases that can hijack and control the UPS system could greatly extend the applicability of degrading molecules. To this end, here we show a potential application of the ELIOT (E3 LIgase pocketOme navigaTor) platform, previously published by this group, for a scaffold-repurposing strategy to identify new ligands for a novel E3 ligase, such as TRIM33. Starting from ELIOT, a case study of the cross-relationship using GRID Molecular Interaction Field (MIF) similarities between TRIM24 and TRIM33 binding sites was selected. Based on the assumption that similar pockets could bind similar ligands and considering that TRIM24 has 12 known co-crystalised ligands, we applied a scaffold-repurposing strategy for the identification of TRIM33 ligands exploiting the scaffold of TRIM24 ligands. We performed a deeper computational analysis to identify pocket similarities and differences, followed by docking and water analysis; selected ligands were synthesised and subsequently tested against TRIM33 via HTRF binding assay, and we obtained the first-ever X-ray crystallographic complexes of TRIM33α with three of the selected compounds.

Indexed as

Proteasome Endopeptidase ComplexUbiquitin-Protein LigasesLigandsProteolysisUbiquitinLigandsProteasome Endopeptidase ComplexUbiquitinUbiquitin-Protein LigasesBRDE3 ligasemolecular interaction fieldsPROTACscaffold-repurposingtargeted protein degradationTRIM24TRIM33

Identifiers

PMID36430693
PMCPMC9698485
OpenAlexW4309457230

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.